Ruxolitinib. Tyrosine-protein kinase JAK1/2 inhibitor, treatment of myelofibrosis, treatment of myeloproliferative neoplasms, treatment of psoriasis

Drugs of the Future

Volumn 35, Issue 6, 2010, Pages 457-465

  Campas Moya C ^a  

^a Advancell   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BORTEZOMIB; ERYTHROMYCIN; HYDROXYUREA; INCB 018424; INCB 28050; KETOCONAZOLE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; RUXOLITINIB; RUXOLITINIB C 14; STAT PROTEIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HEMATOPOIESIS; HUMAN; ISOTOPE LABELING; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHLEBOTOMY; POLYCYTHEMIA; POLYCYTHEMIA VERA; PROSTATE CANCER; PSORIASIS; RHEUMATOID ARTHRITIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84952990437     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.06.1509764     Document Type: Article

References (51)

1. Lin, Q., Meloni, D., Pan, Y. et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett 2009, 11(9): 1999-2002.
2. Rodgers, J.D., Shepard, S., Maduskuie, T.P. Jr. et al. (Incyte Corp.). Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors. US 20090181959.
3. Rodgers, J.D., Shepard, S., Maduskuie, T.P. Jr. et al. (Incyte Corp.). Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors. CA 2632466, EP 1966202, JP 2009519340, US 2007135461, US 7598257, WO 2007070514.
4. Friedman, P.A., Fridman, J.S., Luchi, M.E., Williams, W.V. (Incyte Corp.). Janus kinase inhibitors for treatment of dry eye and other eye related diseases. WO 2010039939.
5. Aaronson, D.S., Horvath, C.M. A road map for those who don't know JAK-STAT. Science 2002, 296(5573): 1653-5.
6. Ferrajoli, A., Faderl, S., Ravandi, F., Estrov, Z. The JAK-STAT pathway: A therapeutic target in hematological malignancies. Curr Cancer Drug Targets 2006, 6(8): 671-9.
7. Constantinescu, S.N., Girardot, M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008, 33(3): 122-31.
8. O'Shea, J.J., Pesu, M., Borie, D.C., Changelian, P.S. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004, 3(7): 555-64.
9. Kishimoto, T., Kikutani, H. Knocking the SOCS off a tumor suppressor. Nat Genet 2001, 28(1): 4-5.
10. Shuai, K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000, 19(21): 2638-44.
11. Darnell, J.E. Validating Stat3 in cancer therapy. Nat Med 2005, 11(6): 595-6.
12. Lacronique, V., Boureux, A., Valle, V.D. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278(5341): 1309-12.
13. Levine, R.L., Gilliland, D.G. Myeloproliferative disorders. Blood 2008, 112(6): 2190-8.
14. Wadleigh, M., Tefferi, A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010, 91(2): 174-9.
15. James, C., Ugo, V., Le Couedic, J.P. et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005, 434(7037): 1144-8.
16. Baxter, E.J., Scott, L.M., Campbell, P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464): 1054-61.
17. Kralovics, R., Passamonti, F., Buser, A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17): 1779-90.
18. Levine, R.L., Wadleigh, M., Cools, J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4): 387-97.
19. Chen, A.T., Prchal, J.T. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol 2010, 17(2): 110-6.
20. Kyle, R.A., Rajkumar, S.V. Multiple myeloma. Blood 2008, 111(6): 2962-72.
21. Galm, O., Yoshikawa, H., Esteller, M., Osieka, R., Herman, J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101(7): 2784-8.
22. Chim, C.S., Fung, T.K., Cheung, W.C., Liang, R., Kwong, Y.L. SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway. Blood 2004, 103(12): 4630-5.
23. Li, J., Favata, M., Kelley, J.A. et al. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia 2010, 12(1): 28-38.
24. Birnie, R., Bryce, S.D., Roome, C. et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008, 9(5): R83.
25. Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M., Edwards, J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007, 97(3): 378-83.
26. Kaminska, B., Swiatek-Machado, K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol 2008, 4(1): 93-112.
27. Quintás-Cardama, A., Vaddi, K., Liu, P. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115(15): 3109-17.
28. Fridman, S., Li, J., Caulder, E. et al. Selective JAK inhibition is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Haematologica [13th Congr Eur Hematol Assoc (EHA) (June 12-15, Copenhagen) 2008] 2008, 93(Suppl. 1): Abst 0956.
29. Shilling, A.D., Nedza, F. In vivo absorption, disposition, metabolism and excretion of 14C-INC018424 in non-clinical species. Drug Metab Rev [16th North Am ISSX Meet (Oct 18-22, Baltimore) 2009] 2009, 41(Suppl. 3): Abst 124.
30. Punwani, N., Gottlieb, A., Birnbaum, J., Birnbaum, J.E., Williams, W. Efficacy and safety of topical INCB018424, a selective Janus kinase 1 & 2 (JAK1&2) inhibitor in psoriasis. J Am Acad Dermatol [67th Annu Meet Am Acad Dermatol (AAD) (March 6-10, San Francisco) 2009] 2009, 60(3, Suppl. 1): Abst P3358.
31. Verstovsek, S., Kantarjian, H., Pardanani, A. et al. The selective janus kinase (JAK) inhibitor, INCB018424, shows efficacy in a phase I/II trial in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (POST-PV/ET MF). Haematologica [13th Congr Eur Hematol Assoc (EHA) (June 12-15, Copenhagen) 2008] 2008, 93(Suppl. 1): Abst 0444.
32. Verstovsek, S., Kantarjian, H.M. A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 7004.
33. Verstovsek, S., Passamonti, F., Rambatdi, A. et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. 51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009, Abst 311.
34. Verstovsek, S., Kantarjian, H.M., Pardanani, A.D. et al. The JAK inhibitor, INCB018424 demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ET-MF). Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1762.
35. Tefferi, A., Kantarjian, H.M., Pardanani, A.D. et al. The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1/2. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 2804.
36. Verstovsek, S., Kantarjian, H.M., Pardanani, A.D. et al. Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: No change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical Improvement following treatment with the JAK inhibitor, INCB018424. Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 2802.
37. Mesa, R.A., Verstovsek, S., Kantarjian, H.M. et al. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and Frank cachexia in patients with myelofibrosis (MF). Blood [50th Annu Meet Am Soc Hematol (Dec 6-9, San Francisco) 2008] 2008, 112(11): Abst 1760.
38. Controlled myelofibrosis study with oral JAK inhibitor treatment: The COMFORT-I Trial (NCT00952289). ClinicalTrials.gov Web site, May 14, 2010.
39. Controlled myelofibrosis study with oral Janus-associated kinase (JAK) inhibitor treatment-II: The COMFORT-II Trial (NCT00934544). ClinicalTrials.gov Web site, May 14, 2010.
40. Ravandi, F., Verstovsek, S., Estrov, Z. et al. Significant activity of the JAK2 inhibitor, INCB018424 in patients with secondary, post- myeloproliferative disorder (MPD) acute myeloid leukemia (sAML): Results of an exploratory phase II study. 51st Annu Meet Am Soc Hematol (Dec 5-8, New Orleans) 2009, Abst 631.
41. INCB018424 in patients with advanced hematologic malignancies conditions (NCT00674479). ClinicalTrials.gov Web site, May 14, 2010.
42. Study of INCB018424 administered orally to patients with androgen independent metastatic prostate cancer (NCT00638378). ClinicalTrials.gov Website, May 14, 2010.
43. This is a study to determine the effect and safety of an oral Janus kinase 2 (JAK2)-inhibitor in patients with multiple myeloma (NCT00639002). ClinicalTrials.gov Web site, May 14, 2010.
44. Punwani, N.G., Williams, W., Scherle, P. et al. Initial efficacy and safety of topical INCB018424 cream, a selective janus kinase 1&2 (JAK1&2) inhibitor in psoriasis. 17th Congr Eur Acad Dermatol Venereol (EADV) (Sept 17-21, Paris) 2008, Abst FP1332.
45. A study of INCB018424 phosphate cream when applied to patients with plaque psoriasis condition: Plaque psoriasis (NCT00820950). ClinicalTrials.gov Web site, May 14, 2010.
46. Fridman, J., Scherle, P., Collins, R. et al. Efficacy and tolerability of novel JAK inhibitors in animal models of rheumatoid arthritis. Arthritis Rheum [71st Annu Sci Meet Am Coll Rheumatol (Nov 6-11, Boston) 2007] 2007, 56(9, Suppl.): Abst 1771.
47. Williams, W.V., Scherle, P., Shi, J. et al. Initial efficacy of INCB018424, a selective Janus kinase1& 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Annu Eur Congr Rheumatol (EULAR) (June 11-14, Paris) 2008, Abst OP-0044.
48. Williams, W., Scherle, P., Shi, J. et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 and 2 (JAK1 and 2) inhibitor arthritis (RA). 72nd Annu Sei Meet Am Coll Rheumatol (Oct 24-29, San Francisco) 2008, Abst 714.
49. INCB028050 compared to background therapy in patients with active rheumatoid arthritis (RA) with inadequate response to disease modifying anti-rheumatic drugs (NCT00902486). ClinicalTrials.gov Web site, May 14, 2010.
50. Shi, J.G., Chen, X.J., Yeleswaram, S., Lo, Y., Scherle, P., Punwam, N., Williams, W. An open-label assessment of the effects of CYP3A4 inhibitors on the PK/PD of INCB018424 in healthy subjects. J Clin Pharmacol [38th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 13-15, San Antonio) 2009] 2009, 49(9): Abst 10.
51. Shi, J.G., Chen, X.J., Yeleswaram, S. et al. An open-label assessment of the effects of rifampin, a potent CYP3A4 inducer on the PK/PD of INCB018424 in healthy subjects. J Clin Pharmacol [38th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 13-15, San Antonio) 2009] 2009, 49(9): Abst 9.